Quarterly report pursuant to Section 13 or 15(d)

Transactions with BioXcel (Details)

v3.20.2
Transactions with BioXcel (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 05, 2018
USD ($)
Nov. 07, 2017
USD ($)
shares
Feb. 29, 2020
USD ($)
shares
Jul. 31, 2019
USD ($)
Apr. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
shares
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
shares
Jun. 30, 2019
USD ($)
Dec. 31, 2019
shares
Transactions with BioXcel                    
Common shares, issued | shares           20,352,913   20,352,913   18,087,382
Payments to repurchase shares     $ 9,024         $ 9,024    
Shares repurchased (in shares) | shares     300,000         300,000    
BioXcel Corporation | Asset contribution agreement                    
Transactions with BioXcel                    
Common shares, issued | shares   9,480,000                
Lump sum payment to parent   $ 5,000                
Period specified for payment   60 days                
Cumulative net sales   $ 50,000                
Payment to (received from) related party $ 1,000     $ 500 $ 500          
BioXcel Corporation | Collaborative services agreement                    
Transactions with BioXcel                    
Term of agreement   5 years                
BioXcel Corporation | Development milestones                    
Transactions with BioXcel                    
Potential milestone payments   $ 10,000                
BioXcel Corporation | Sales milestones                    
Transactions with BioXcel                    
Potential milestone payments   $ 30,000                
Maximum milestone (as as percent)   3                
BioXcel Corporation | Separation and Shared Services Agreement                    
Transactions with BioXcel                    
Service charges           $ 259 $ 223 $ 656 $ 516  
BioXcel Corporation | Payable upon milestones | Asset contribution agreement                    
Transactions with BioXcel                    
Lump sum payment to parent   $ 1,000                
BioXcel Corporation | Payable upon later 12 months IPO and first dosing for BXCL501 | Asset contribution agreement                    
Transactions with BioXcel                    
Lump sum payment to parent   $ 500                
Period specified for payment   12 months                
BioXcel Corporation | Payable upon later of 12 months of IPO and specified milestones | Asset contribution agreement                    
Transactions with BioXcel                    
Lump sum payment to parent   $ 500                
Period specified for payment   12 months